Biohaven Ltd (NYSE:BHVN) has a beta value of 3.84 and has seen 1.29 million shares traded in the last trading session. The company, currently valued at $3.96B, closed the last trade at $39.12 per share which meant it lost -$2.32 on the day or -5.60% during that session. The BHVN stock price is -59.02% off its 52-week high price of $62.21 and 31.49% above the 52-week low of $26.80. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.91 million shares traded. The 3-month trading volume is 1.05 million shares.
The consensus among analysts is that Biohaven Ltd (BHVN) is Buy stock at the moment, with a recommendation rating of 1.13. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 7 have rated it as a Hold, with 7 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -1.66.
Biohaven Ltd (NYSE:BHVN) trade information
Sporting -5.60% in the red in last session, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the BHVN stock price touched $39.12 or saw a rise of 10.68%. Year-to-date, Biohaven Ltd shares have moved -8.60%, while the 5-day performance has seen it change -8.15%. Over the past 30 days, the shares of Biohaven Ltd (NYSE:BHVN) have changed -11.87%. Short interest in the company has seen 7.84 million shares shorted with days to cover at 9.66.
Wall Street analysts have a consensus price target for the stock at $59, which means that the shares’ value could jump 33.69% from current levels. The projected low price target is $55.0 while the price target rests at a high of $65.0. In that case, then, we find that the current price level is -66.16% off the targeted high while a plunge would see the stock gain -40.59% from current levels.
Biohaven Ltd (BHVN) estimates and forecasts
Figures show that Biohaven Ltd shares have underperformed across the wider relevant industry. The company’s shares have gained 19.38% over the past 6 months, with this year growth rate of -54.45%, compared to 17.20% for the industry. Revenue growth from the last financial year stood is estimated to be 0.00%.
11 analysts offering their estimates for the company have set an average revenue estimate of 9.09M for the current quarter. 5 have an estimated revenue figure of 2.5M for the next ending quarter.
BHVN Dividends
Biohaven Ltd is expected to release its next earnings report in January this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Biohaven Ltd (NYSE:BHVN)’s Major holders
Insiders own 11.16% of the company shares, while shares held by institutions stand at 87.11% with a share float percentage of 98.05%. Investors are also buoyed by the number of investors in a company, with Biohaven Ltd having a total of 354.0 institutions that hold shares in the company. The top two institutional holders are VANGUARD GROUP INC with over 7.27 million shares worth more than $252.41 million. As of 2024-06-30, VANGUARD GROUP INC held 8.9114% of shares outstanding.
The other major institutional holder is STIFEL FINANCIAL CORP, with the holding of over 6.48 million shares as of 2024-06-30. The firm’s total holdings are worth over $224.94 million and represent 7.9417% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF . As of Sep 30, 2024 , the former fund manager holds about 2.40% shares in the company for having 2.43 shares of worth $95.13 million while later fund manager owns 1.95 shares of worth $76.39 million as of Sep 30, 2024 , which makes it owner of about 1.93% of company’s outstanding stock.
